JP2025509507A5 - - Google Patents
Info
- Publication number
- JP2025509507A5 JP2025509507A5 JP2024554630A JP2024554630A JP2025509507A5 JP 2025509507 A5 JP2025509507 A5 JP 2025509507A5 JP 2024554630 A JP2024554630 A JP 2024554630A JP 2024554630 A JP2024554630 A JP 2024554630A JP 2025509507 A5 JP2025509507 A5 JP 2025509507A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- formula
- substituted alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320503P | 2022-03-16 | 2022-03-16 | |
| US63/320,503 | 2022-03-16 | ||
| PCT/US2023/064416 WO2023178167A1 (en) | 2022-03-16 | 2023-03-15 | Asymmetric piperazine-based cationic lipids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509507A JP2025509507A (ja) | 2025-04-11 |
| JP2025509507A5 true JP2025509507A5 (https=) | 2026-03-26 |
Family
ID=85979858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554630A Pending JP2025509507A (ja) | 2022-03-16 | 2023-03-15 | 非対称ピペラジン系カチオン性脂質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20260021055A1 (https=) |
| EP (1) | EP4493548A1 (https=) |
| JP (1) | JP2025509507A (https=) |
| CN (1) | CN118922409A (https=) |
| TW (1) | TW202345835A (https=) |
| WO (1) | WO2023178167A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN121219273A (zh) * | 2023-11-02 | 2025-12-26 | 深圳厚存纳米药业有限公司 | 脂质和脂质纳米颗粒制剂 |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| WO2025250906A1 (en) | 2024-05-30 | 2025-12-04 | Aera Therapeutics, Inc. | Process for preparation of targeted lipid nanoparticles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2016205691A1 (en) * | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| AU2017357758B2 (en) | 2016-11-10 | 2023-11-16 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| WO2020227085A1 (en) * | 2019-05-03 | 2020-11-12 | Translate Bio, Inc. | Di-thioester cationic lipids |
| WO2021226468A1 (en) * | 2020-05-07 | 2021-11-11 | Translate Bio, Inc. | Improved compositions for cftr mrna therapy |
| IL301536A (en) * | 2020-09-23 | 2023-05-01 | Translate Bio Inc | Cationic lipids based on piperazine |
-
2023
- 2023-03-15 WO PCT/US2023/064416 patent/WO2023178167A1/en not_active Ceased
- 2023-03-15 JP JP2024554630A patent/JP2025509507A/ja active Pending
- 2023-03-15 TW TW112109520A patent/TW202345835A/zh unknown
- 2023-03-15 EP EP23716125.2A patent/EP4493548A1/en active Pending
- 2023-03-15 CN CN202380028029.8A patent/CN118922409A/zh active Pending
- 2023-03-15 US US18/847,135 patent/US20260021055A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025509507A5 (https=) | ||
| JP2023542944A5 (https=) | ||
| JP2022520061A5 (https=) | ||
| JP2023098949A (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP2023520047A5 (https=) | ||
| JP2018070614A5 (https=) | ||
| JP2020505403A5 (https=) | ||
| JP2008514223A5 (https=) | ||
| CA2499622A1 (en) | Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders | |
| ES2830447T3 (es) | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación | |
| JP2001247459A5 (https=) | ||
| JP2022548155A5 (https=) | ||
| JP2005504053A5 (https=) | ||
| JP2021534160A5 (https=) | ||
| JP2023548307A5 (https=) | ||
| JP2023545924A5 (https=) | ||
| EP4292651A2 (en) | Liponucleotide-based therapy for ards | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| KR20190064573A (ko) | 혈액 암 치료용 PPARγ 작용제 | |
| JP2021514380A5 (ja) | 筋障害及び骨障害を処置するための化合物及び組成物 | |
| US10010505B2 (en) | Liposomes active in-vivo on neurodegenerative diseases | |
| JP2003507434A (ja) | 関節症、関節炎、及び他のリウマチ性関節疾患を治療するための医療用調製物 | |
| JP2018529747A5 (https=) | ||
| ES3061642T3 (en) | Dosing regimens for treatment of proliferative disorders | |
| JP2007169300A (ja) | 進行癌の処置のためのテモゾロミドとα−ＩＦＮの組合せ |